


## Supplementary Figures and Tables

### Supplementary Figure 1. UVA radiation increased double-stranded DNA breaks and ROS.

**(a)** g-H2AX intensity was synergistically increased with the combination of CX-5461 and UVA radiation. Representative pictures of g-H2AX immunofluorescent staining with and without UVA radiation, for control, CX5461  $10^{-8}$ M, CX5461  $5 \times 10^{-8}$ M, PDS  $20 \times 10^{-6}$ M, representative images from 30 fields per condition, quantified in **(b)** Quantile and mean intensity of g-H2AX level per cell, vertical axis. UV and drug factor conditions, horizontal axis. Experiments were repeated two times (biological duplicates) and similar results were obtained. Number of cells as in Figure 5g **(c)** The ratio of ROS level measured after UVA irradiation versus before UVA irradiation was calculated. Biological triplicates. The horizontal bar = median. \*\*\* $P < 0.0001$ , Welch's t-test;  $n = 8$



Supplementary Figure



**Supplementary Table 2:** Supplemental response information. 36 patients were fully evaluable for response (1 patient was not treated, and 4 patients were not reassessed)

Best Response	All treated patients N=40		BRCA1 / 2 or PALB2 germline or somatic mutations		BRCA1 / 2, PALB2 pr TP53 germline or somatic mutations		All treated patients N=40	
	N patients	Response Duration Mo. Median (range)	N patients	Response Duration Mo. Median (range)	N patients	Response Duration Mo. Median (range)	Prior Platinum N (%) N= 32	Prior PARP Inhibitor N (%) N=8
Complete Response (CR)	0							
Partial Response (PR)	4	6.5 ( 5.5- 8.2)	3	6.3 (5.5-6.8)	4	6.5 (5.5-8.2)	2	
Stable Disease (SD)	11	3.6 ( 2.3- 10.9)	7	3.5 (3-9.2)	7	3.5 (3-9.2)	8	1
Progressive Disease (PD)	21		12		15		18	6
Inevaluable	4		3		3		4	1

**Supplementary Table 3.** Schedule for collection of CX5461 pharmacokinetics

Cycle and Day	Time
C1D1	Pre-infusion
	During infusion at 30 minutes
	Immediately post infusion then:
	30 minutes post infusion
	1 hour post infusion
	2 hours post infusion
	4 hours post infusion
6 hours post infusion*	
C1D2	24 hours post infusion
C1D3	48 hours post infusion
C1D4	72 hours post infusion
C1D8	Pre-infusion
C1D15	Pre-infusion
	During infusion at 30 minutes
	Immediately post infusion then
	30 minutes post infusion
	1 hour post infusion
	2 hours post infusion
	4 hours post infusion
6 hours post infusion*	
C1D16	24 hours post infusion
C1D17-19	single sample: 48-96 hours after C1D15 infusion
C2D1	Pre-infusion
* May be 6-8 hours.	

In addition to the specific time points listed above, additional samples were to be collected from consenting patients with unusual or severe toxicity, or initial PK results suggest unusual PK or exposure.